LFA-REAL offers a straight-forward evaluation for lupus-affected organ systems, a study shows.
Anifrolumab, a type 1 interferon receptor antagonist, performs well in early trial, researchers show.
Patients sometimes insist on non-traditional therapies after a rheumatoid arthritis diagnosis. Their concerns shouldn't be ignored and instead, patients should be counseled on therapeutic options.
Facing a growing shortage, rheumatology is looking to attract the next generation of providers.
Retaining international medical students, addressing student loan debt, mentoring and case-based teaching could possibly reverse the rheumatologist shortage, analysis says.
In this Q&A we feature a conversation with Felipe Andrade, M.D., Ph.D., of the Johns Hopkins University School of Medicine in Baltimore.
The 2015 recommendations for PsA treatment highlight the importance of managing comorbidities and a patient-centered treatment approach.
Predictive modeling data can steer physicians toward making healthcare decisions that have positive outcomes for patients.
Q&A: Two experts discuss proposals for formal CVD risk calculators in RA and the need for long-term research to validate them.
Identifying quality indicators will be important under MACRA. Some say quality indicators are true measurements that reflect the standard of care.